Search
Search Results
##search.searchResults.foundPlural##
-
The Outcome of Six Patients with COVID-19 Infection and Multiple Myeloma. A Case Series and Literature Review COVID-19 in Multiple Myeloma patients
902PDF: 331HTML: 167 -
REGULATORY T-CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA
2254PDF: 939HTML: 7606Untitled: 254Fig2: 163Fig3: 143Fig4: 162 -
WALDENSTROM’S MACROGLOBULINEMIA: AN UPDATE
7241PDF: 2372HTML: 1705Table 1.: 183Table 2.: 199Table 3.: 180Table 4.: 179 -
Guest Editor: Pellegrino Musto REFINING HIGH-RISK MULTIPLE MYELOMA: ADVANCEMENTS IN GENOMIC, CLINICAL, AND PROGNOSTIC CRITERIA Multiple Myeloma High Risk Classificatio
2075PDF: 1524HTML: 248 -
TOXICITIES ASSOCIATED WITH CAR-T CELL THERAPIES CAR-T Cell Toxicity
1929PDF: 1360HTML: 246 -
NON-SECRETORY MYELOMA: READY FOR A NEW DEFINITION?
3146PDF: 1683HTML: 1071 -
HODGKIN LYMPHOMA IN OLDER PATIENTS: AN ORPHAN DISEASE?
2808PDF: 1310HTML: 3551Untitled: 171Untitled: 186Untitled: 162 -
CAR-T CELL THERAPY FOR FOLLICULAR LYMPHOMAS CAR-T and Follicular Lymphoma
2081PDF: 1740HTML: 119 -
OUTCOME OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA RELAPSING AFTER AUTOLOGOUS TRANSPLANT BEFORE AVAILABILITY OF CAR-T CELL TREATMENT Outcome of DLBCL patients relapsing after ASCT
1228HTML: 282PDF: 899Suppl. Files: 431 -
FLT3 Mutated Acute Myeloid Leukemia after CD19 CAR-T Cells
901PDF: 1180HTML: 89 -
CHRONIC MYELOPROLIFERATIVE NEOPLASMS: A COLLABORATIVE APPROACH
1607PDF: 698HTML: 2327 -
TREATMENT OUTCOMES AND CLINICAL RELEVANCE IN PATIENTS WITH DOUBLE EXPRESSOR DLBCL Sirapat Rungwittayatiwat1, Paisarn Boonsakan2, Pichika Chantrathammachart1, Teeraya Puavilai1, Sulada Pukiat1, Sithakom Phusanti1,3, Kochawan Boonyawat1, Pathawut Wacharapornin1, Pantep Angchaisuksiri1, Artit Ungkanont1,3, Suporn Chuncharunee1 Pimjai Niparuck1
1042PDF: 465HTML: 168 -
Aberrant acquisition of T-cell associated markers in plasma cell neoplasms: An aggressive disease with extramedullary involvement and very short survival Aberrant T markers on malignant plasma cells
1440PDF: 353HTML: 183 -
QUALITY OF LIFE ASSESSMENT IN MULTIPLE MYELOMA PATIENTS UNDERGOING DOSE-REDUCED TANDEM AUTOLOGOUS STEM CELL TRANSPLANTATION
1353PDF: 645HTML: 1364cover letter: 188 -
Hsa-miR-5581-3p and hsa-miR-542-3p target the F8 gene in hemophilia A without F8 mutations F8 gene is regulated by miRNAs
1072PDF: 459HTML: 212 -
EBV-RELATED LYMPHOPROLIFERATIVE DISEASES: A REVIEW IN LIGHT OF NEW CLASSIFICATIONS EBV-RELATED LYMPHOPROLIFERATIVE DISEASES
3999PDF: 1534HTML: 840 -
DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES: ANALOGIES AND DIFFERENCES DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES
1297HTML: 368PDF: 793 -
CHIMERIC ANTIGEN RECEPTOR T CELLS FOR THE TREATMENT OF MULTIPLE MYELOMA CAR T Cells and Myeloma Treatment
1648PDF: 796HTML: 137







